UNITE Glioblastoma
  • About
    • Participating Institutions
    • Governance
      • Spokesperson and Co-Spokespersons
      • Steering Committee Members
      • Project Management Team
    • Gender equality and family friendly measures
  • Research
    • Focus A
      • A01: Targeting tumor cell network communication to overcome primary and adaptive resistance in glioblastoma
      • A02: Development of a specific combination therapy for histone H3-mutant pediatric glioblastoma
      • A03: Deciphering resistance against targeted treatments
      • A04: Elucidating tumor-associated microglia interactions in astrocytomas CNS WHO-grade 4
      • A05: Predictive biomarkers for MGMT-promoter-methylated glioblastoma (2019 – 2023)
      • A06: Resistance mechanisms of glioblastoma against alkylating agents and radiotherapy
      • A07: Mapping and targeting neuron-tumor networks to tackle therapy resistance in glioblastoma
      • A08: Personalized glioblastoma treatment guided by patient-derived tumor organoids
    • Focus B
      • B01: Mechanisms of response and resistance to glioma-specific t cells
      • B02: DNA mis-match repair regulates immune checkpoint blockade therapy in glioblastoma (2019 – 2023)
      • B03: Targeting immunosuppressive programs in isocitrate dehydrogenase mutant gliomas
      • B04: Impact of myeloid cells on the adaptive immune response in newly diagnosed and recurrent glioblastomas
      • B05: Dissecting the response of glioblastoma and its tumor microenvironment to focused high-dose radiotherapy (2019 – 2023)
      • B06: Visualization and characterization of immune responses in H3K27M mutant gliomas
      • B07A: Targeting the post-radiogenic tumor microenvironment
    • Focus C
      • C01: Comprehensive preclinical pharmacology testing of drugs used for glioblastoma treatment
      • C02: Radiomics, radiogenomics and deep-learning in neurooncology
      • C03: Imaging immune signatures of glioma response and resistance towards immunotherapy (2019 – 2023)
      • C04: Metabolic signaling in glioblastoma: a spatial multi-omics approach
      • C05: Overcoming glioma radio-resistance with particle therapy
      • C06: Functional characterization of EGFR structural variants associated with long-term survival in glioblastoma, IDH-WT
    • Focus D
      • D01: Integrated tissue core
      • D02: Data integration, bioinformatics analysis, and data exploration for precision neurooncology
      • D03: Integrated research training group – UNITE School of Neurooncology
      • UNITE Core Collection
  • Members
  • Events
    • Past Events
  • School
    • Fellows
  • News
  • Contact
  • Menu

UNITE EVENTS

uniklinikHD Neuro6162carinakircher

INTERNAL

UNITE WORK IN PROGRESS MEETING

A01/A02/A03

17.09.2026, 10:15-11:15h, in person (P)

uniklinikHD Neuro7293carinakircher external speaker

INTERNAL

UNITE JOURNAL CLUB

C02/D01/D02

24.09.2026, 10:15-11:15h, in person (P)

uniklinikHD Neuro6162carinakircher

INTERNAL

UNITE WORK IN PROGRESS MEETING

A04/A06/A07N

08.10.2026, 10:15-11:15h, virtual (V)

uniklinikHD Neuro7293carinakircher external speaker

INTERNAL

UNITE JOURNAL CLUB

A01/A02

15.10.2026, 10:15-11:15h, in person (P)

uniklinikHD Neuro6162carinakircher

INTERNAL

UNITE WORK IN PROGRESS MEETING

A08N/B01/B02

22.10.2026, 10:15-11:15h, in person (P)

Seminar Series 5 1

EXTERNAL

UNITE SEMINAR SERIES

TBD

05.11.2026, 10:15-11:15h, in person (P)

uniklinikHD Neuro7293carinakircher external speaker

INTERNAL

UNITE JOURNAL CLUB

A03/A04

12.11.2026, 10:15-11:15h, in person (P)

uniklinikHD Neuro6162carinakircher

INTERNAL

UNITE WORK IN PROGRESS MEETING

B04/B06N/B07N

19.11.2026, 10:15-11:15h, virtual (V)

uniklinikHD Neuro6162carinakircher

INTERNAL

UNITE WORK IN PROGRESS MEETING

C01/C02/C04

26.11.2026, 10:15-11:15h, in Person (P)

uniklinikHD Neuro7293carinakircher external speaker

INTERNAL

UNITE JOURNAL CLUB

A06/A07N

03.12.2026, 10:15-11:15h, in person (P)

uniklinikHD Neuro6162carinakircher

INTERNAL

UNITE WORK IN PROGRESS MEETING

C05/C06N/D01

10.12.2026, 10:15-11:15h, virtual (V)

20251216 140155 1

INTERNAL/EXTERNAL

UNITE SCIENTIFIC RETREAT

All WPs

17.12.-18.12.2026, in person (P)

uniklinikHD Neuro6162carinakircher

INTERNAL

UNITE WORK IN PROGRESS MEETING

D02/D03/D04

21.01.2027, 10:15-11:15h, in person (P)

uniklinikHD Neuro7293carinakircher external speaker

INTERNAL

UNITE JOURNAL CLUB

A08/B01

28.01.2027, 10:15-11:15h, in person (P)

Seminar Series 5 1

EXTERNAL

UNITE SEMINAR SERIES

TBD

04.02.2027, 10:15-11:15h, in person (P)

uniklinikHD Neuro6162carinakircher

INTERNAL

UNITE WORK IN PROGRESS MEETING

A01/A02/A03

18.02.2027, 10:15-11:15h, virtual(V)

CONTACT

BERGS, JUDITH, PH.D.

BERGS, JUDITH, PH.D.

Scientific Coordinator

University Hospital Heidelberg, Department of Neurology, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany

UNITE Glioblastoma
CV / Publications
Malburg, Cara, M. Sc.

Malburg, Cara, M. Sc.

Project Coordinator

University Hospital Heidelberg, Department of Neurology, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany

UNITE Glioblastoma
CV / Publications
COLE, KATJA, B.A.

COLE, KATJA, B.A.

Student Research Assistant

University Hospital Heidelberg, Department of Neurology, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany

UNITE Glioblastoma
CV / Publications

Address

Im Neuenheimer Feld 400
69120 Heidelberg

Themen

  • About
  • Research
  • Members
  • Events
  • School
  • News
  • Contact

Research

  • Focus A
    • A01: Targeting tumor cell network communication to overcome primary and adaptive resistance in glioblastoma
    • A02: Development of a specific combination therapy for histone H3-mutant pediatric glioblastoma
    • A03: Deciphering resistance against targeted treatments
    • A04: Elucidating tumor-associated microglia interactions in astrocytomas CNS WHO-grade 4
    • A05: Predictive biomarkers for MGMT-promoter-methylated glioblastoma (2019 – 2023)
    • A06: Resistance mechanisms of glioblastoma against alkylating agents and radiotherapy
    • A07: Mapping and targeting neuron-tumor networks to tackle therapy resistance in glioblastoma
    • A08: Personalized glioblastoma treatment guided by patient-derived tumor organoids

Research

  • Focus B
    • B01: Mechanisms of response and resistance to glioma-specific t cells
    • B02: DNA mis-match repair regulates immune checkpoint blockade therapy in glioblastoma (2019 – 2023)
    • B03: Targeting immunosuppressive programs in isocitrate dehydrogenase mutant gliomas
    • B04: Impact of myeloid cells on the adaptive immune response in newly diagnosed and recurrent glioblastomas
    • B05: Dissecting the response of glioblastoma and its tumor microenvironment to focused high-dose radiotherapy (2019 – 2023)
    • B06: Visualization and characterization of immune responses in H3K27M mutant gliomas

Research

  • Focus C
    • C01: Comprehensive preclinical pharmacology testing of drugs used for glioblastoma treatment
    • C02: Radiomics, radiogenomics and deep-learning in neurooncology
    • C03: Imaging immune signatures of glioma response and resistance towards immunotherapy (2019 – 2023)
    • C04: Metabolic signaling in glioblastoma: a spatial multi-omics approach
    • C05: Overcoming glioma radio-resistance with particle therapy
    • C06: Functional characterization of EGFR structural variants associated with long-term survival in glioblastoma, IDH-WT

Research

  • Focus D
    • D01: Integrated tissue core
    • D02: Data integration, bioinformatics analysis, and data exploration for precision neurooncology
    • D03: Integrated research training group – UNITE School of Neurooncology
    • UNITE Core Collection
© UNITE Glioblastoma since 2020 | Designed & Developed by Bärenstark
  • Privacy Policy
  • Impressum
  • Contact
Scroll to top

This site uses cookies. By continuing to use the site, you consent to the use of cookies.

Accept settingsShow settings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy Page
Accept all servicesSave settings
Open Message Bar